Thrombin and Plasmin Generation in Patients with Plasminogen or Plasminogen Activator Inhibitor Type 1 Deficiency

Overview

Journal Haemophilia

Specialty Hematology

Date 2019 Aug 31

PMID 31469483

Citations 10

Authors

Joline L Saes

Saskia E M Schols

Kathleen F Betbadal

Mark van Geffen

Kitty Verbeek-Knobbe

Sweta Gupta

Brandon M Hardesty

Amy D Shapiro

Waander L van Heerde

Affiliations

Soon will be listed here.

Abstract

Introduction: Deficiencies of plasminogen and plasminogen activator inhibitor type 1 (PAI-1) are rare disorders of fibrinolysis. Current laboratory assays for analysis of activity of plasminogen and PAI-1 do not provide an accurate correlation with clinical phenotype.

Methods: The Nijmegen Hemostasis Assay (NHA) was used to simultaneously measure thrombin and plasmin generation in 5 patients with plasminogen deficiency (PLGD) and 10 patients with complete PAI-1 deficiency. Parameters analysed included: lag time ratio, thrombin peak time ratio, thrombin peak height, thrombin potential (AUC), fibrin lysis time, plasmin peak height and plasmin potential. Parameters were expressed as a percentage compared to a reference value of 53 healthy normal controls.

Results: Patients with PLGD demonstrated a short lag time and thrombin peak time, with normal thrombin peak height but an increased AUC. Plasmin generation was able to be detected in only one (23% plasminogen activity) of the five PLGD patients. All ten PAI-1 deficient patients demonstrated a short lag and thrombin peak time, low thrombin peak height with normal AUC. Plasmin generation revealed an increased plasmin peak and plasmin potential; interestingly, there was a large variation between individual patients despite all patients having the same homozygous defect.

Conclusion: Patients with either PLGD or PAI-1 deficiency show distinct abnormalities in plasmin and thrombin generation in the NHA. The differences observed in the propagation phase of thrombin generation may be explained by plasmin generation. These results suggest that disorders of fibrinolysis also influence coagulation and a global assay measuring both activities may better correlate with clinical outcome.

Citing Articles

Enhanced thrombin and plasmin generation profiles in alpha-2-antiplasmin-deficient patients: Data from the Rare Bleeding disorders in the Netherlands study.

Haisma B, Rijpma S, Cnossen M, den Exter P, Kruis I, Meijer K Res Pract Thromb Haemost. 2024; 8(7):102604.

PMID: 39628652 PMC: 11613267. DOI: 10.1016/j.rpth.2024.102604.

Plasmin generation analysis in patients with bleeding disorder of unknown cause.

Mehic D, Reitsma S, de Moreuil C, Haslacher H, Koeller M, de Laat B Blood Adv. 2024; 8(21):5663-5673.

PMID: 39231312 PMC: 11564053. DOI: 10.1182/bloodadvances.2024012855.

Plasminogen missense variants and their involvement in cardiovascular and inflammatory disease.

Brito-Robinson T, Ayinuola Y, Ploplis V, Castellino F Front Cardiovasc Med. 2024; 11:1406953.

PMID: 38984351 PMC: 11231438. DOI: 10.3389/fcvm.2024.1406953.

Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A.

Strilchuk A, Hur W, Batty P, Sang Y, Abrahams S, Yong A Sci Transl Med. 2024; 16(735):eadh0027.

PMID: 38381848 PMC: 11293256. DOI: 10.1126/scitranslmed.adh0027.

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype.

Verhagen M, Heerde W, van der Bom J, Beckers E, Blijlevens N, Coppens M Res Pract Thromb Haemost. 2023; 7(2):100062.

PMID: 36865907 PMC: 9971314. DOI: 10.1016/j.rpth.2023.100062.

References

Ewald G, Eisenberg P . Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation. 1995; 91(1):28-36. DOI: 10.1161/01.cir.91.1.28. View

Mingers A, HEIMBURGER N, Zeitler P, Kreth H, Schuster V . Homozygous type I plasminogen deficiency. Semin Thromb Hemost. 1997; 23(3):259-69. DOI: 10.1055/s-2007-996099. View

Saes J, Schols S, Betbadal K, van Geffen M, Verbeek-Knobbe K, Gupta S . Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2019; 25(6):1073-1082. PMC: 6899449. DOI: 10.1111/hae.13842. View

Rick M, Krizek D . Platelets modulate the proteolysis of factor VIII:C protein by plasmin. Blood. 1986; 67(6):1649-54. View

Brandt J . Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med. 2002; 126(11):1376-81. DOI: 10.5858/2002-126-1376-PATTPA. View

Young G, Carmona R, Garcia V . Thromboelastography and thrombin generation assay in inherited afibrinogenemia. Haemophilia. 2018; 24(6):e410-e416. DOI: 10.1111/hae.13620. View

Fay W, Parker A, Condrey L, Shapiro A . Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997; 90(1):204-8. View

Minowa H, Takahashi Y, Tanaka T, Naganuma K, Ida S, MAKI I . Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis. 2000; 29(5):286-91. DOI: 10.1159/000022514. View

Omar M, Mann K . Inactivation of factor Va by plasmin. J Biol Chem. 1987; 262(20):9750-5. View

10.

Fay W, Shapiro A, Shih J, Schleef R, Ginsburg D . Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992; 327(24):1729-33. DOI: 10.1056/NEJM199212103272406. View

11.

Terry K, Buckley L, Aldemerdash A, Fanikos J, Dellorfano H . Fibrinolytic and Anticoagulation Therapy in Patients Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis for Pulmonary Embolism. Cardiovasc Hematol Disord Drug Targets. 2017; 17(2):132-135. DOI: 10.2174/1871529X17666170908110328. View

12.

Sartori M, Patrassi G, Theodoridis P, Perin A, Pietrogrande F, Girolami A . Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds. Blood Coagul Fibrinolysis. 1994; 5(6):889-93. DOI: 10.1097/00001721-199412000-00004. View

13.

Iwaki T, Tanaka A, Miyawaki Y, Suzuki A, Kobayashi T, Takamatsu J . Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost. 2011; 9(6):1200-6. DOI: 10.1111/j.1538-7836.2011.04288.x. View

14.

Osterud B, Laake K, Prydz H . The activation of human factor IX. Thromb Diath Haemorrh. 1975; 33(3):553-63. View

15.

Lotan T, Tefs K, Schuster V, Miller J, Manaligod J, Filstead A . Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. Hum Pathol. 2007; 38(10):1569-75. DOI: 10.1016/j.humpath.2007.05.007. View

16.

Pitkanen H, Jouppila A, Lemponen M, Ilmakunnas M, Ahonen J, Lassila R . Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement. Thromb Res. 2016; 149:56-61. DOI: 10.1016/j.thromres.2016.11.012. View

17.

Lee M, Vosburgh E, Anderson K, McDonagh J . Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood. 1993; 81(9):2357-62. View

18.

Matsumoto T, Nogami K, Shima M . Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost. 2013; 110(4):761-8. DOI: 10.1160/TH13-04-0345. View

19.

Meltzer M, Lisman T, de Groot P, Meijers J, le Cessie S, Doggen C . Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood. 2010; 116(1):113-21. DOI: 10.1182/blood-2010-02-267740. View

20.

Grundy J, Lavigne N, Hirama T, MacKenzie C, Pryzdial E . Binding of plasminogen and tissue plasminogen activator to plasmin-modulated factor X and factor Xa. Biochemistry. 2001; 40(21):6293-302. DOI: 10.1021/bi002209v. View